Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-news-1/study-points-to-new-uses--unexpected-side-effects-of-already-existing-drugs-10627-2/;/a></li><li><a) was not found.

Search biology news 1 study points to new uses unexpected side effects of already existing drugs 10627 2 ; a>< li><li><a at Google

Search biology news 1 study points to new uses unexpected side effects of already existing drugs 10627 2 ; a>< li><li><a at Yahoo

Search biology news 1 study points to new uses unexpected side effects of already existing drugs 10627 2 ; a>< li><li><a at Msn

Google
 
(Date:12/4/2009)... CORVALLIS, Ore. According to an analysis of statewide ... less than $50,000 a year were more than three ... health providers because of their insurance status during pregnancy ... discrimination was also three times more likely among mothers ...
(Date:12/4/2009)... Royal Botanic Gardens, Kew and the Natural History Museum ... widespread than previously thought, with many commonly grown plants ... to being "meat eaters". A review paper, Murderous plants: ... is published today (4 December 2009) in the ...
(Date:12/4/2009)... is available in German . , A ... Ageing could help to understand the positive effect of dietary ... flies and mice) have shown that dietary restriction increases longevity, ... So the female fruit fly reproduces less frequently with a ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8
(Date:12/6/2009)... avoid oysters harvested from San Antonio Bay ,, ... Food and Drug Administration is advising consumers to avoid ... or after Nov. 16 due to reports of norovirus-associated ... from this area, which is located on the Gulf ... ) ,, The FDA, along with the Centers for ...
(Date:12/6/2009)... by researchers from the Medical College of Wisconsin, in ... pain and other sickle cell disease complications in children. ... providers and patients were also identified. The study ... of pediatrics at the Medical College and Children,s Research ... presented at the American Society of Hematology meeting Dec. ...
(Date:12/6/2009)... www.sleeping-with-a-sleeping-disorder.com is asking people ,who have ... aids from around the world to donate their ... submissions will be compiled in an ebook titled ... be sold from the website in early January ... proceeds ,from sales of the E-book to three ...
(Date:12/5/2009)... Dec. 5 ,, What: Cuts for ... difference in the fight against cancer and other terminal illnesses ... be donated to St. Jude Children,s Research Hospital. Guests will ... a delectable and savory Vietnamese restaurant in Falls Church for ...
(Date:12/5/2009)... Research debunks the ,something,s wrong with being single, myth , , ... people who pass their 40th birthday without ever tying the ... health woes than married folks. And, um, isn,t there something ... so fast. , A new study looking at psychological measures ...
Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... This depletion cocktail is ... (CD3+CD4+CD8+) cells from suspensions of ... Cells are separated using the ... immunomagnetic negative selection system, achieving ...
...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... selection system. The CD4+ T ...
Biology Products:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products:
(Date:12/2/2009)... NEW YORK, Dec. 2 Nearly 600 medical research ... explore novel development approaches and innovative funding strategies at ... ,, FasterCures, the Washington-based center of the ... facilitate multi-sector collaborations needed to turn a scientific discovery ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going ... part of many,businesses and industries. It turns out that ... downturn, because illness doesn,t take a,vacation. , ... this year, the pharmaceutical,giant Johnson & Johnson inaugurated an ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
(Date:12/4/2009)... Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ... investor teleconference and webcast. Principal investigators will discuss ... multiple myeloma, as featured at the 51st American Society ... begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, ...
(Date:12/4/2009)... Corporation (Nasdaq: DYNT ) announced it has signed ... rehab supplies to Benchmark Physical Therapy with 65 clinics ... pleased to be named the sole-source supplier to Benchmark ... of sales and marketing at Dynatronics. "Benchmark is known ...
(Date:12/4/2009)... Amex: PIP ), a biodefense company developing medical ... presentation of new data from the Company,s anthrax vaccine ... based anthrax vaccine is structurally stable and potent after ... 55 degrees C. The data were presented by ...
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Cardiva Medical Inc Announces the Departure of its President and his Appointment as CEO of Innovative Energy Inc 5468 1Cardiva Medical Inc Announces the Departure of its President and his Appointment as CEO of Innovative Energy Inc 5468 2Cardiva Medical Inc Announces the Departure of its President and his Appointment as CEO of Innovative Energy Inc 5468 3Solos Endoscopy Inc s FDA Approved MammoView 28TM 29 Product Line to Obtain CE Mark 5465 1Solos Endoscopy Inc s FDA Approved MammoView 28TM 29 Product Line to Obtain CE Mark 5465 2National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 1National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 2National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 3